Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01366404
Other study ID # CVRF2010-09
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 2011
Est. completion date April 2026

Study information

Verified date July 2023
Source CardioVascular Research Foundation, Korea
Contact Seung-Jung Park, MD, PhD
Email sjpark@amc.seoul.kr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

About 15,000 patients with FFR (Fractional Flow Reserve) will be enrolled and evaluated for the natural history of coronary lesions at 2 years clinical and imaging follow-up.


Description:

This is a multicenter, prospective cohort. About 15,000 patients with FFR will be enrolled at multi centres in Korea.


Recruitment information / eligibility

Status Recruiting
Enrollment 15000
Est. completion date April 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender All
Age group 35 Years and older
Eligibility Inclusion Criteria: - Age 35 years and older - FFR measurement on one and more coronary artery stenosis - Willing and able to provide informed, written consent Exclusion Criteria: - Stenosis with TIMI<3 flow - Graft vessel - Ejection fraction < 30% - Angiographic evidence of extreme tortuosity or calcified coronary vessels - Suspected coronary spasm even after sufficient nitrate injected - Life expectancy <2 year - Planned cardiac surgery or planned major non cardiac surgery - Woman who are breastfeeding, pregnant or planning to become pregnant during the course of the study Imaging study specific exclusion criteria - visually-estimated angiographic reference segment diameter of <2.75mm or >4.0mm - Inappropriate for IVUS/VH/OCT procedures : inability for imaging wire or catheter to pass through the tight stenosis, severe calcification, angulation

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Korea, Republic of Hallym University Sacred Heart Hospital Anyang
Korea, Republic of Soon Chun Hyang University Hospital Bucheon Bucheon
Korea, Republic of Chungbuk National University Hospital Cheongju
Korea, Republic of Gangwon National Univ. Hospital Chuncheon
Korea, Republic of Daegu Catholic University Center Daegu
Korea, Republic of Keimyung University Dongsan Medical Center Daegu
Korea, Republic of Kyungpook National university hospital Daegu
Korea, Republic of Yeungnam University Medical Center Daegu
Korea, Republic of Chungnam National University Hospital Daejeon
Korea, Republic of The Catholic University of Korea, Deajeon St.Mary's hospital Daejeon
Korea, Republic of Gangneung Asan Hospital Gangneung
Korea, Republic of Chonnam National University Hospital Gwangju
Korea, Republic of Inje University Ilsan Paik Hospital Ilsan
Korea, Republic of Dong-A Medical Center Pusan
Korea, Republic of Pusan National University Hospital Pusan
Korea, Republic of Seoul university Bundang hospital Seongnam
Korea, Republic of Asan Medical Center Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Hallym University Kangdong Sacred Heart Hospital Seoul
Korea, Republic of Korea University Anam Hospital Seoul
Korea, Republic of Korea University Guro Hospital Seoul
Korea, Republic of Kyung-Hee University Hospital at Kangdong Seoul
Korea, Republic of Seoul National University Boramae Medical Center Seoul
Korea, Republic of Seoul National University Hospital Seoul
Korea, Republic of The Catholic University of Korea, Seoul St.Mary's Hospital Seoul
Korea, Republic of The Catholic University of Korea, Yeouido St. Mary's Hospital Seoul
Korea, Republic of Ulsan University Hospital Ulsan
Korea, Republic of Wonju Severance Christian Hospital Wonju
Korea, Republic of Pusan National University Yangsan Hospital Yangsan

Sponsors (3)

Lead Sponsor Collaborator
Seung-Jung Park Abbott Medical Devices, CardioVascular Research Foundation, Korea

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Target vessel failure 2 year after index FFR measurement
Primary composite Cardiac Death,Non Fatal Myocardial Infarction, Target Vessel Revascularization, and Indeterminate events at 2 year after index FFR measurement
Secondary Death (all cause and cardiac) at 2 year after index FFR measurement
Secondary MI at 2 year after index FFR measurement
Secondary Target vessel revascularization at 2 year after index FFR measurement
Secondary Target lesion revascularization at 2 year after index FFR measurement
Secondary Any re-hospitalization with a cardiac cause 2 year follow-up after index FFR measurement
Secondary cardiac death and myocardial infarction 2 year follow-up after index FFR measurement
Secondary stented lesion related event including death, myocardial infarction, repeat revascularization 2 year follow-up after index FFR measurement
Secondary stroke 2 year follow-up after index FFR measurement
Secondary stent thrombosis 2 year follow-up after index FFR measurement
Secondary anginal status 2 year follow-up after index FFR measurement
Secondary number of anti-anginal medication prescribed 2 year follow-up after index FFR measurement
Secondary complication of FFR measurement 2 year follow-up after index FFR measurement
Secondary clinical predictors of events 2 year follow-up after index FFR measurement
Secondary change in plaque composition (%necrotic core volume) in target segment 2 year follow-up after index FFR measurement
Secondary change in plaque type assessed by VH(Virtual Histology) and OCT(Optical coherence tomography) 2 year follow-up after index FFR measurement
Secondary change in total atheroma volume and percent atheroma volume 2 year follow-up after index FFR measurement
Secondary change in IVUS-measured MLA 2 year follow-up after index FFR measurement
Secondary change in FFR 2 year follow-up after index FFR measurement
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Coronary De Novo Lesions N/A